<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK476443" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK476443/" /><meta name="ncbi_pagename" content="TANGO2-Related Metabolic Encephalopathy and Arrhythmias - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>TANGO2-Related Metabolic Encephalopathy and Arrhythmias - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="TANGO2-Related Metabolic Encephalopathy and Arrhythmias" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/12/20" /><meta name="citation_author" content="Seema R Lalani" /><meta name="citation_author" content="Brett Graham" /><meta name="citation_author" content="Lindsay Burrage" /><meta name="citation_author" content="Yi-Chen Lai" /><meta name="citation_author" content="Fernando Scaglia" /><meta name="citation_author" content="Claudia Soler-Alfonso" /><meta name="citation_author" content="Christina Miyake" /><meta name="citation_author" content="Yaping Yang" /><meta name="citation_pmid" content="29369572" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK476443/" /><meta name="citation_keywords" content="Transport and Golgi organization protein 2 homolog" /><meta name="citation_keywords" content="TANGO2" /><meta name="citation_keywords" content="TANGO2-Related Metabolic Encephalopathy and Arrhythmias" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="TANGO2-Related Metabolic Encephalopathy and Arrhythmias" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Seema R Lalani" /><meta name="DC.Contributor" content="Brett Graham" /><meta name="DC.Contributor" content="Lindsay Burrage" /><meta name="DC.Contributor" content="Yi-Chen Lai" /><meta name="DC.Contributor" content="Fernando Scaglia" /><meta name="DC.Contributor" content="Claudia Soler-Alfonso" /><meta name="DC.Contributor" content="Christina Miyake" /><meta name="DC.Contributor" content="Yaping Yang" /><meta name="DC.Date" content="2018/12/20" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK476443/" /><meta name="description" content="Individuals with TANGO2-related metabolic encephalopathy and arrhythmias can present in acute metabolic crisis (hypoglycemia, elevated lactate, mild hyperammonemia) or with developmental delay, regression, and/or seizures. The acute presentation varies from profound muscle weakness, ataxia, and/or disorientation to a comatose state. Individuals can present with intermittent acute episodes of rhabdomyolysis. The first episode of myoglobinuria has been known to occur as early as age five months. Acute renal tubular damage due to myoglobinuria can result in acute kidney injury and renal failure. During acute illness, transient electrocardiogram changes can be seen; the most common is QT prolongation. Life-threatening recurrent ventricular tachycardia or torsade de pointes occurs primarily during times of acute illness. Individuals who do not present in metabolic crises may present with gait incoordination, progressively unsteady gait, difficulty with speech, or clumsiness. Intellectual disability of variable severity is observed in almost all individuals. Seizures are observed outside the periods of crises in more than 75% of individuals. Hypothyroidism has been reported in more than one third of individuals." /><meta name="og:title" content="TANGO2-Related Metabolic Encephalopathy and Arrhythmias" /><meta name="og:type" content="book" /><meta name="og:description" content="Individuals with TANGO2-related metabolic encephalopathy and arrhythmias can present in acute metabolic crisis (hypoglycemia, elevated lactate, mild hyperammonemia) or with developmental delay, regression, and/or seizures. The acute presentation varies from profound muscle weakness, ataxia, and/or disorientation to a comatose state. Individuals can present with intermittent acute episodes of rhabdomyolysis. The first episode of myoglobinuria has been known to occur as early as age five months. Acute renal tubular damage due to myoglobinuria can result in acute kidney injury and renal failure. During acute illness, transient electrocardiogram changes can be seen; the most common is QT prolongation. Life-threatening recurrent ventricular tachycardia or torsade de pointes occurs primarily during times of acute illness. Individuals who do not present in metabolic crises may present with gait incoordination, progressively unsteady gait, difficulty with speech, or clumsiness. Intellectual disability of variable severity is observed in almost all individuals. Seizures are observed outside the periods of crises in more than 75% of individuals. Hypothyroidism has been reported in more than one third of individuals." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK476443/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/tango2-mea/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK476443/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8BCC20E04074010000000007140289.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK476443_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK476443_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/cdsp/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/tardbp-als/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK476443_"><span class="title" itemprop="name"><i>TANGO2</i>-Related Metabolic Encephalopathy and Arrhythmias</span></h1><p class="contrib-group"><span itemprop="author">Seema R Lalani</span>, MD, <span itemprop="author">Brett Graham</span>, MD, PhD, <span itemprop="author">Lindsay Burrage</span>, MD, PhD, <span itemprop="author">Yi-Chen Lai</span>, MD, <span itemprop="author">Fernando Scaglia</span>, MD, <span itemprop="author">Claudia Soler-Alfonso</span>, MD, <span itemprop="author">Christina Miyake</span>, MD, MS, and <span itemprop="author">Yaping Yang</span>, PhD.</p><a data-jig="ncbitoggler" href="#__NBK476443_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK476443_ai__"><div class="contrib half_rhythm"><span itemprop="author">Seema R Lalani</span>, MD<div class="affiliation small">Associate Professor, Department of Molecular and Human Genetics<br />Baylor College of Medicine<br />Houston, Texas<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.cmt.mcb@lamees" class="oemail">ude.cmt.mcb@lamees</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Brett Graham</span>, MD, PhD<div class="affiliation small">Associate Professor, Department of Molecular and Human Genetics<br />Indiana University School of Medicine<br />Indianapolis, Indiana<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.ui@ahargerb" class="oemail">ude.ui@ahargerb</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Lindsay Burrage</span>, MD, PhD<div class="affiliation small">Assistant Professor, Department of Pediatrics<br />Baylor College of Medicine<br />Houston, Texas<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.mcb@egarrub" class="oemail">ude.mcb@egarrub</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Yi-Chen Lai</span>, MD<div class="affiliation small">Assistant Professor, Department of Pediatrics<br />Section of Critical Care<br />Baylor College of Medicine<br />Houston, Texas<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.mcb@ialy" class="oemail">ude.mcb@ialy</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Fernando Scaglia</span>, MD<div class="affiliation small">Professor, Department of Molecular and Human Genetics<br />Baylor College of Medicine<br />Houston, Texas<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.mcb@ailgacsf" class="oemail">ude.mcb@ailgacsf</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Claudia Soler-Alfonso</span>, MD<div class="affiliation small">Assistant Professor, Department of Molecular and Human Genetics<br />Baylor College of Medicine<br />Houston, Texas<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.mcb@relos" class="oemail">ude.mcb@relos</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Christina Miyake</span>, MD, MS<div class="affiliation small">Associate Professor, Department of Pediatrics<br />Section of Cardiology<br />Associate Professor, Molecular Physiology and Biophysics<br />Baylor College of Medicine<br />Houston, Texas<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.mcb@ekayimyc" class="oemail">ude.mcb@ekayimyc</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Yaping Yang</span>, PhD<div class="affiliation small">Associate Professor, Department of Molecular and Human Genetics<br />Baylor College of Medicine<br />Houston, Texas<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.mcb@ygnipay" class="oemail">ude.mcb@ygnipay</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">January 25, 2018</span>; Last Update: <span itemprop="dateModified">December 20, 2018</span>.</p><p><em>Estimated reading time: 18 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="tango2-mea.Summary" itemprop="description"><h2 id="_tango2-mea_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Individuals with <i>TANGO2</i>-related metabolic encephalopathy and arrhythmias can present in acute metabolic crisis (hypoglycemia, elevated lactate, mild hyperammonemia) or with developmental delay, regression, and/or seizures. The acute presentation varies from profound muscle weakness, ataxia, and/or disorientation to a comatose state. Individuals can present with intermittent acute episodes of rhabdomyolysis. The first episode of myoglobinuria has been known to occur as early as age five months. Acute renal tubular damage due to myoglobinuria can result in acute kidney injury and renal failure. During acute illness, transient electrocardiogram changes can be seen; the most common is QT prolongation. Life-threatening recurrent ventricular tachycardia or <i>torsade de pointes</i> occurs primarily during times of acute illness. Individuals who do not present in metabolic crises may present with gait incoordination, progressively unsteady gait, difficulty with speech, or clumsiness. Intellectual disability of variable severity is observed in almost all individuals. Seizures are observed outside the periods of crises in more than 75% of individuals. Hypothyroidism has been reported in more than one third of individuals.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of <i>TANGO2</i>-related metabolic encephalopathy and arrhythmias is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>TANGO2</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i></p><ul><li class="half_rhythm"><div><i>Acute presentation:</i> Early management during episodes of metabolic crises with aggressive intravenous hydration and urine alkalinization. Cardiac monitoring should include an early electrocardiogram (ECG), continuous ECG monitoring, and an echocardiogram to determine cardiac function. Arrhythmia management by an electrophysiologist is preferred; monitor electrolytes and treat as necessary to maintain normal levels of potassium, magnesium, and glucose; levothyroxine for hypothyroidism and steroid treatment for adrenal insufficiency, if determined. .</div></li><li class="half_rhythm"><div><i>Non-acute presentation:</i> Standard treatment of developmental delay/intellectual disability; levothyroxine is the treatment of choice for hypothyroidism. Antiepileptics have been used for management of seizures.</div></li></ul><p><i>Prevention of primary manifestations:</i> Avoidance of triggers for acute metabolic crisis (e.g., prolonged fasting, dehydration, ketogenic diet). Infusion of intravenous glucose during significant acute periods of systemic metabolic stress caused by infection or general anesthesia may be required to prevent significant catabolism.</p><p><i>Prevention of secondary complications:</i> Provide hydration and alkalinization of the urine during an attack of rhabdomyolysis and myoglobinuria to prevent renal failure. An "emergency" plan should be in place to initiate steps to suppress acute catabolism and promote hydration in order to minimize the risk of life-threatening rhabdomyolysis and cardiac arrhythmias. Prior to determining the rate and amount of fluid administration, an echocardiogram to assess cardiac function should be considered.</p><p><i>Surveillance:</i> Regular cardiology evaluation for management of cardiac arrhythmias; annual TSH and free T4; neurology follow up to manage epilepsy.</p><p><i>Agents/circumstances to avoid:</i> Fasting; dehydration; ketogenic diet, which can precipitate severe metabolic crises.</p><p><i>Evaluation of relatives at risk:</i> It is appropriate to clarify the genetic status of apparently asymptomatic older and younger sibs of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> to allow prompt initiation of treatment and preventive measures.</p></div><div><h4 class="inline">Genetic counseling.</h4><p><i>TANGO2</i>-related metabolic encephalopathy and arrhythmias is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Once the <i>TANGO2</i> pathogenic variants have been identified in an affected family member, <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a> for at-risk relatives, prenatal testing for a pregnancy at increased risk, and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p></div></div><div id="tango2-mea.Diagnosis"><h2 id="_tango2-mea_Diagnosis_">Diagnosis</h2><p>The diagnostic criteria for <i>TANGO2</i>-related metabolic encephalopathy and arrhythmias have not yet been established.</p><div id="tango2-mea.Suggestive_Findings"><h3>Suggestive Findings</h3><p><i>TANGO2</i>-related metabolic encephalopathy and arrhythmias <b>should be suspected</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the following clinical, supportive laboratory, and radiographic findings.</p><p><b>Clinical findings</b></p><ul><li class="half_rhythm"><div>Recurrent acute metabolic crises (see <b>Supportive laboratory findings</b>)</div></li><li class="half_rhythm"><div>Profound episodic muscle weakness</div></li><li class="half_rhythm"><div>Ataxia</div></li><li class="half_rhythm"><div>Disorientation</div></li><li class="half_rhythm"><div>Coma</div></li><li class="half_rhythm"><div>Intermittent dysphagia</div></li><li class="half_rhythm"><div>Cardiac arrhythmias</div></li><li class="half_rhythm"><div>Developmental delay</div></li><li class="half_rhythm"><div>Intellectual disability</div></li><li class="half_rhythm"><div>Regression of motor and cognitive skills</div></li><li class="half_rhythm"><div>Poor coordination and unsteady gait</div></li><li class="half_rhythm"><div>Dysarthria</div></li><li class="half_rhythm"><div>Myopathic facies</div></li><li class="half_rhythm"><div>Seizures</div></li></ul><p><b>Supportive laboratory findings</b></p><ul><li class="half_rhythm"><div>Recurrent episodes of acute metabolic crises (hypoglycemia, elevated lactate, mild hyperammonemia)</div></li><li class="half_rhythm"><div>Elevated creatine phosphokinase, aldolase, and transaminases</div></li><li class="half_rhythm"><div>Recurrent rhabdomyolysis</div></li><li class="half_rhythm"><div>Hypothyroidism</div></li><li class="half_rhythm"><div><a href="/books/n/gene/gr_22q11deletion/">22q11.2 deletion syndrome</a> and recurrent acute metabolic crises and rhabdomyolysis</div></li></ul><p><b>Brain MRI findings.</b> Cerebral volume loss</p></div><div id="tango2-mea.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of <i>TANGO2</i>-related metabolic encephalopathy and arrhythmias <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by the identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>TANGO2</i> (see <a class="figpopup" href="/books/NBK476443/table/tango2-mea.T.molecular_genetic_testing_u/?report=objectonly" target="object" rid-figpopup="figtango2meaTmoleculargenetictestingu" rid-ob="figobtango2meaTmoleculargenetictestingu">Table 1</a>).</p><p>Molecular genetic testing approaches can include a combination of <b><a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted testing</b> (single-gene testing or a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>) and <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (genomic sequencing) depending on the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p>Gene-targeted testing requires that the clinician determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>(s) are likely involved, whereas <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing does not. Because the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of <i>TANGO2</i>-related metabolic encephalopathy and arrhythmias is broad, individuals with the distinctive findings of rhabdomyolysis and cardiac arrhythmias in the setting of metabolic derangements such as hypoglycemia, elevated lactate, and mild hyperammonemia are likely to be diagnosed using <b>single-gene testing</b> or a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> (see <a href="#tango2-mea.Option_1">Option 1</a>), whereas those with a phenotype indistinguishable from many other inherited disorders associated with developmental delay and/or intellectual disability are more likely to be diagnosed using <b>genomic testing</b> (see <a href="#tango2-mea.Option_2">Option 2</a>).</p><div id="tango2-mea.Option_1"><h4>Option 1</h4><p><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> includes <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> and gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> of <i>TANGO2</i>.</p><p>Targeted analysis for pathogenic variants can be performed first in selected populations:</p><ul><li class="half_rhythm"><div>In individuals of Hispanic ancestry, targeted analysis for <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a class="figpopup" href="/books/NBK476443/table/tango2-mea.T.tango2_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figtango2meaTtango2pathogenicvariants" rid-ob="figobtango2meaTtango2pathogenicvariants">p.Gly154Arg</a></div></li><li class="half_rhythm"><div>In individuals of European ancestry, targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> analysis for the ~34-kb deletion encompassing exons 3-9</div></li></ul><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>TANGO2</i> and other genes of interest (see <a href="#tango2-mea.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered; however, given how recently <i>TANGO2-</i>related metabolic encephalopathy and arrhythmias were identified, many panels may not include this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p><p>Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p></div><div id="tango2-mea.Option_2"><h4>Option 2</h4><p><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, mitochondrial sequencing, and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> or genes that results in a similar clinical presentation).</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> for disorders associated with developmental delay and/or intellectual disability that includes <i>TANGO2</i> and other genes of interest (see <a href="#tango2-mea.Differential_Diagnosis">Differential Diagnosis</a>) may be also considered; however, given how recently <i>TANGO2-</i>related metabolic encephalopathy and arrhythmias were identified, many panels may not include this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p><div id="tango2-mea.T.molecular_genetic_testing_u" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>TANGO2</i>-Related Metabolic Encephalopathy and Arrhythmias</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK476443/table/tango2-mea.T.molecular_genetic_testing_u/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tango2-mea.T.molecular_genetic_testing_u_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_tango2-mea.T.molecular_genetic_testing_u_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_tango2-mea.T.molecular_genetic_testing_u_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_tango2-mea.T.molecular_genetic_testing_u_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_tango2-mea.T.molecular_genetic_testing_u_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>TANGO2</i></td><td headers="hd_h_tango2-mea.T.molecular_genetic_testing_u_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_tango2-mea.T.molecular_genetic_testing_u_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~50%&#x000a0;<sup>4,&#x000a0;5</sup></td></tr><tr><td headers="hd_h_tango2-mea.T.molecular_genetic_testing_u_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>6</sup></td><td headers="hd_h_tango2-mea.T.molecular_genetic_testing_u_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~50%&#x000a0;<sup>4,&#x000a0;5</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="tango2-mea.TF.1.1"><p class="no_margin">See <a href="/books/NBK476443/#tango2-mea.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="tango2-mea.TF.1.2"><p class="no_margin">See <a href="#tango2-mea.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="tango2-mea.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="tango2-mea.TF.1.4"><p class="no_margin">Detection rate varies with the ethnicity of the individual being tested.</p></div></dd><dt>5. </dt><dd><div id="tango2-mea.TF.1.5"><p class="no_margin"><a class="bk_pop" href="#tango2-mea.REF.kremer.2016.358">Kremer et al [2016]</a>, <a class="bk_pop" href="#tango2-mea.REF.lalani.2016.347">Lalani et al [2016]</a>, <a class="bk_pop" href="#tango2-mea.REF.dines.2019.601">Dines et al [2019]</a></p></div></dd><dt>6. </dt><dd><div id="tango2-mea.TF.1.6"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd></dl></div></div></div></div></div></div><div id="tango2-mea.Clinical_Characteristics"><h2 id="_tango2-mea_Clinical_Characteristics_">Clinical Characteristics</h2><div id="tango2-mea.Clinical_Description"><h3>Clinical Description</h3><p>Individuals with <i>TANGO2</i>-related metabolic encephalopathy and arrhythmias can present in acute metabolic crisis or with developmental delay, regression, and/or seizures.</p><p><b>Acute metabolic crises.</b> The acute presentation varies from profound muscle weakness, ataxia, and/or disorientation to a comatose state, frequently precipitated by an acute illness or fasting. Individuals can present with intermittent acute episodes of rhabdomyolysis. Dark urine due to myoglobinuria and profound lower-extremity weakness can develop. The first episode of myoglobinuria has been known to occur as early as age five months. Creatine phosphokinase (CPK) can be significantly elevated in some individuals (&#x0003e;200,000 U/l). Elevated aldolase and transaminases are also reported, indicative of muscle injury. During an acute crisis, hypoglycemia, elevated lactate, and mild hyperammonemia can also be seen. Urine organic acids can show marked ketoacidosis and lactic acidosis. Acylcarnitine profiles during acute episodes may show elevated C14:1 in some individuals and elevated C10 species in others. Metabolic abnormalities typically normalize after the metabolic crisis, although some individuals continue to have mildly elevated CPK levels.</p><p><b>Renal complications.</b> Acute renal tubular damage due to myoglobinuria can result in acute kidney injury and renal failure [<a class="bk_pop" href="#tango2-mea.REF.elsayed.2010.7">Elsayed &#x00026; Reilly 2010</a>].</p><p><b>Cardiac dysfunction and ventricular arrhythmias.</b> During acute illness, transient ECG changes and echocardiographic changes can be seen. The most common ECG finding, seen almost universally among <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals in crisis, is marked QT prolongation (often &#x0003e;500 msec) and, rarely, Brugada type I pattern. Life-threatening recurrent ventricular tachycardia (VT) or <i>torsade de pointes</i> occurs primarily during times of acute illness and metabolic crises and can result in hemodynamic instability. Recalcitrant VT unresponsive to antiarrhythmic treatment leading to in-hospital death as well as out-of-hospital unexplained sudden death has been reported. Affected individuals can also demonstrate ventricular dilation and episodic systolic dysfunction during crisis. Hypertrophic cardiomyopathy has been reported in one individual [<a class="bk_pop" href="#tango2-mea.REF.dines.2019.601">Dines et al 2019</a>].</p><p><b>Motor development.</b> Baseline gait incoordination, progressively unsteady gait, difficulty with speech, or clumsiness is frequently reported in ambulatory individuals, even prior to the first episode of acute myoglobinuria.</p><p>Spasticity of lower extremities, hyperreflexia, and clonus have been reported. Dysarthria, myopathic facies, intermittent head tilt, and drooling can be observed in individuals between acute metabolic crises.</p><p><b>Intellectual disability</b> of variable severity is observed in almost all individuals with <i>TANGO2</i>-related metabolic encephalopathy and arrhythmias. It is unclear whether this is an inherent feature of the disorder or a sequela of multiple metabolic crises experienced over time.</p><p><b>Seizures</b> are observed outside the periods of crises in more than 75% of individuals. A variety of seizure types have been reported, including generalized myoclonic and atonic seizures. Seizures are generally responsive to antiepileptic medications in individuals with <i>TANGO2</i>-related metabolic encephalopathy and arrhythmias, although refractory epilepsy has been reported [<a class="bk_pop" href="#tango2-mea.REF.dines.2019.601">Dines et al 2019</a>].</p><p><b>Brain imaging abnormalities.</b> Prominent lateral ventricles, with progressive brain atrophy on MRI examination, have been reported in several <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. While some older individuals have normal brain imaging studies, generalized cerebral atrophy has been described in young infants with early disease presentation.</p><p><b>Endocrinopathy.</b> Hypothyroidism has been reported in more than one third of individuals with <i>TANGO2</i>-related metabolic encephalopathy and arrhythmias. Elevated serum thyroid stimulating hormone (TSH) and low free T4 are seen, consistent with primary hypothyroidism. The <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are typically diagnosed with hypothyroidism during acute crises with evaluation for muscle weakness or altered mental status. Adrenal insufficiency may also occur.</p><p><b>Ophthalmology.</b> Intermittent exotropia has been observed in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. Rare individuals have been diagnosed with optic atrophy.</p><p><b>Hearing loss.</b> Sensorineural hearing loss has been described in rare instances.</p><p><b>Gastrointestinal concerns.</b> Dysphagia and episodic worsening of swallow function has been observed, increasing the risk of aspiration due to inability to manage secretions and liquids. Delayed gastric emptying with gastrointestinal dysmotility are additional concerns. Some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have required gastrostomy tube feedings [<a class="bk_pop" href="#tango2-mea.REF.dines.2019.601">Dines et al 2019</a>]. Acute pancreatitis in the setting of prolonged hospitalization has been seen in one individual.</p></div><div id="tango2-mea.GenotypePhenotype_Correlation"><h3>Genotype-Phenotype Correlations</h3><p>No clear <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> exist.</p></div><div id="tango2-mea.Penetrance"><h3>Penetrance</h3><p>To date, <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in those with <i>TANGO2</i> pathogenic variants is 100%. There is known <a class="def" href="/books/n/gene/glossary/def-item/variable-expressivity/">variable expressivity</a> with this disorder.</p></div><div id="tango2-mea.Nomenclature"><h3>Nomenclature</h3><p><i>TANGO2</i>-related metabolic encephalopathy and arrhythmias is referred to as "metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration" (MECRCN) in OMIM.</p></div><div id="tango2-mea.Prevalence"><h3>Prevalence</h3><p>The minor <a class="def" href="/books/n/gene/glossary/def-item/allele-frequency/">allele frequency</a> (MAF) of the <a class="figpopup" href="/books/NBK476443/table/tango2-mea.T.tango2_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figtango2meaTtango2pathogenicvariants" rid-ob="figobtango2meaTtango2pathogenicvariants">c.460G&#x0003e;A</a> (p.Gly154Arg) variant in the Hispanic/Latino population is estimated at 0.26%. The ~34-kb <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> encompassing exons 3-9 is observed with an approximate allele frequency of 0.11% in white Europeans. The majority of the reported individuals to date are of Hispanic or European ancestry. Consanguineous families from Turkey and of Middle Eastern origin with <a class="def" href="/books/n/gene/glossary/def-item/private/">private</a> pathogenic variants (both intragenic deletions and sequence variants) have been described.</p></div></div><div id="tango2-mea.Genetically_Related_Allelic_D"><h2 id="_tango2-mea_Genetically_Related_Allelic_D_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>TANGO2</i>.</p></div><div id="tango2-mea.Differential_Diagnosis"><h2 id="_tango2-mea_Differential_Diagnosis_">Differential Diagnosis</h2><div id="tango2-mea.T.disorders_to_consider_in_th" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Disorders to Consider in the Differential Diagnosis of <i>TANGO2</i>-Related Metabolic Encephalopathy and Arrhythmias</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK476443/table/tango2-mea.T.disorders_to_consider_in_th/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tango2-mea.T.disorders_to_consider_in_th_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Clinical Features of This Disorder</th></tr><tr><th headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_4" id="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping w/<i>TANGO2</i>-Related MEA</th><th headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_4" id="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing from <i>TANGO2</i>-Related MEA</th></tr></thead><tbody><tr><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mitochondrial disorder (see <a href="/books/n/gene/mt-overview/">Mitochondrial Disorders Overview</a>)</td><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Many</td><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR or maternal inheritance</td><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_4 hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Lactic acidosis, myopathy, seizures</td><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_4 hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Not seen: ventricular tachycardia in the setting of acute metabolic crisis</td></tr><tr><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/cpt2/">Carnitine palmitoyltransferase II deficiency</a></td><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CPT2</i></td><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_4 hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Muscle weakness during attacks, myoglobinuria, cardiac arrhythmias, seizures, coma after infection or prolonged fasting</td><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_4 hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Liver failure, hypoketotic hypoglycemia</td></tr><tr><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Carnitine acylcarnitine translocase deficiency (OMIM <a href="https://omim.org/entry/212138" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">212138</a>)</td><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SLC25A20</i></td><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_4 hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ventricular tachycardia, cardiomyopathy, rhabdomyolysis, hyperammonemia, abnormal liver enzymes, &#x02191; long chain acylcarnitines</td><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_4 hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Typically, &#x02191; C16 &#x00026; C18 (although C14:1 can also be &#x02191;). Not seen: prolongation of QT interval</td></tr><tr><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/vlcad/">Very long-chain acyl-CoA dehydrogenase deficiency</a></td><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ACADVL</i></td><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_4 hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Arrhythmias, rhabdomyolysis, intermittent hypoglycemia</td><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_4 hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypoketotic hypoglycemia, hepatomegaly</td></tr><tr><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Acute recurrent myoglobinuria (OMIM <a href="https://omim.org/entry/268200" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">268200</a>)</td><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>LPIN1</i></td><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_4 hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Muscle weakness, acute recurrent rhabdomyolysis, myoglobinuria</td><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_4 hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Not seen: seizures &#x00026; cardiac arrhythmias</td></tr><tr><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/gsd5/">Glycogen storage disease type V</a> &#x00026; other defects of glucose/glycogen metabolism</td><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PYGM</i></td><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_4 hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Recurrent rhabdomyolysis, myoglobinuria</td><td headers="hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_1_4 hd_h_tango2-mea.T.disorders_to_consider_in_th_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Muscle cramps<br />Not seen: seizures &#x00026; cardiac arrhythmias</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">&#x02191; = elevated; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; MEA = metabolic encephalopathy and arrhythmias; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a></p></div></dd></dl></div></div></div></div><div id="tango2-mea.Management"><h2 id="_tango2-mea_Management_">Management</h2><div id="tango2-mea.Evaluations_Following_Initial"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with <i>TANGO2</i>-related metabolic encephalopathy and arrhythmias, the following evaluations summarized in <a class="figpopup" href="/books/NBK476443/table/tango2-mea.T.recommended_evaluation_of_i/?report=objectonly" target="object" rid-figpopup="figtango2meaTrecommendedevaluationofi" rid-ob="figobtango2meaTrecommendedevaluationofi">Table 3</a> (if not performed as part of the evaluation that led to the diagnosis) are recommended.</p><div id="tango2-mea.T.recommended_evaluation_of_i" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Recommended Evaluation of Individuals with <i>TANGO2</i>-Related Metabolic Encephalopathy and Arrhythmias</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK476443/table/tango2-mea.T.recommended_evaluation_of_i/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tango2-mea.T.recommended_evaluation_of_i_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Presentation</th><th id="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:top;">Evaluation</th></tr></thead><tbody><tr><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_1" rowspan="10" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Acute</b><br /><b>(acute metabolic crisis)</b></td><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neurologic</td><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assessment of ataxic gait, profound lower-extremity weakness</td></tr><tr><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" rowspan="3" colspan="1" scope="row" style="text-align:left;vertical-align:middle;">Cardiovascular</td><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Baseline ECG. Serial ECGs &#x00026; continuous monitoring for life-threatening ventricular arrhythmias is recommended.</td></tr><tr><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Baseline echocardiogram to identify ventricular dysfunction</td></tr><tr><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Ensure access to an ICU &#x00026;, in case of recalcitrant arrhythmia, ECMO capability should be available.</td></tr><tr><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Metabolic</td><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Urine organic acids, acylcarnitine profile, plasma lactate, ammonia, blood glucose, CPK, urine myoglobin, &#x00026; aldolase</td></tr><tr><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" rowspan="2" colspan="1" scope="row" style="text-align:left;vertical-align:middle;">Endocrinologic</td><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">TSH, free T4 to evaluate for hypothyroidism</td></tr><tr><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Cortisol levels for adrenal insufficiency, if suspected</td></tr><tr><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Critical care</td><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assessment of rhabdomyolysis during metabolic crises, renal failure, &#x00026; ventricular arrhythmias</td></tr><tr><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" rowspan="2" colspan="1" scope="row" style="text-align:left;vertical-align:middle;">Gastrointestinal</td><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Monitor dysphagia &#x00026; be aware of episodic worsening, which can increase risk of aspiration due to inability to manage secretions &#x00026; liquids.</td></tr><tr><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Lipase for pancreatitis, if suspected</td></tr><tr><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_1" rowspan="7" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Non-acute</b></td><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Development</td><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neurodevelopmental evaluation</td></tr><tr><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Neurologic</td><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Referral to neurologist for EEG if seizures are suspected &#x00026; if spasticity is present</td></tr><tr><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Cardiovascular</td><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Referral to cardiac electrophysiologist. Baseline ECG, Holter, echocardiogram w/continuous intermittent monitoring. Consider implantable loop recorder.</td></tr><tr><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Metabolic</td><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CPK</td></tr><tr><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Endocrinologic</td><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">TSH, free T4 to evaluate for hypothyroidism</td></tr><tr><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Ophthalmologic</td><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluate for strabismus, optic atrophy</td></tr><tr><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Audiologic</td><td headers="hd_h_tango2-mea.T.recommended_evaluation_of_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluate for hearing loss</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">CPK = creatine phosphokinase; ECMO = extracorporeal membrane oxygenation; ICU = intensive care unit</p></div></dd></dl></div></div></div></div><div id="tango2-mea.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Early management during episodes of <b>metabolic crises</b> is paramount; provide appropriate intravenous fluids with glucose to maintain normoglycemia and promote anabolism (see <a class="figpopup" href="/books/NBK476443/table/tango2-mea.T.acute_treatment_acute_metab/?report=objectonly" target="object" rid-figpopup="figtango2meaTacutetreatmentacutemetab" rid-ob="figobtango2meaTacutetreatmentacutemetab">Table 4</a>).</p><div id="tango2-mea.T.acute_treatment_acute_metab" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Acute Treatment (Acute Metabolic Crisis) in Individuals with <i>TANGO2</i>-Related Metabolic Encephalopathy and Arrhythmias</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK476443/table/tango2-mea.T.acute_treatment_acute_metab/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tango2-mea.T.acute_treatment_acute_metab_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:top;">Manifestation/Concern</th><th id="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Treatment</th><th id="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Consideration/Other</th></tr></thead><tbody><tr><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_1" rowspan="2" colspan="2" scope="row" style="text-align:left;vertical-align:middle;"><b>Rhabdomyolysis</b></td><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Aggressive IV hydration, often at 1.5x &#x02013; 2x maintenance rate</td><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To prevent acute kidney injury</td></tr><tr><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Urine alkalinization to pH of &#x02265;7.0 using sodium bicarbonate-containing fluid, &#x00026; forced diuresis using mannitol may be considered as adjunct therapies.</td><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hemodialysis may be indicated for severe fluid overload &#x00026; electrolyte derangements.&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_1" rowspan="14" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cardiac arrhythmias&#x000a0;<sup>2,&#x000a0;3</sup></b></td><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>General</b></td><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Antiarrhythmic treatment choice should be tailored to arrhythmia presentation.</td><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Continuous ECG monitoring w/arrhythmia management by an electrophysiologist is recommended.</td></tr><tr><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_1" rowspan="3" colspan="1" scope="row" style="text-align:left;vertical-align:middle;"><b>Recurrent VT or <i>TdPs</i></b> resulting in hemodynamic instability:</td><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rhythm should be monitored closely.</td><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_3" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;">Treatment w/multiple IV antiarrhythmic medications, in addition to direct current cardioversion, may be required.</td></tr><tr><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Single PVCs are harbingers for VT. Those w/PVCs should be treated in ICU setting.</td></tr><tr><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Direct current cardioversion is acutely effective but VT/VF is often recurrent &#x00026; recalcitrant.</td></tr><tr><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">If <b>Brugada changes</b> are noted:</td><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Avoid sodium-channel-blocking agents (e.g., procainamide, amiodarone).</td><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">If <b>QT interval is normal</b>:</td><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">IV sotalol, procainamide, or amiodarone can be considered.</td><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">QTc is almost uniformly prolonged during crisis &#x00026; thus these drugs may not be options for treatment.</td></tr><tr><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_1" rowspan="7" colspan="1" scope="row" style="text-align:left;vertical-align:middle;">In the setting of <b>QT prolongation</b>, monitor closely for any PVCs:&#x000a0;<sup>4,&#x000a0;5</sup></td><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Maintain magnesium levels &#x0003e;2 mg/dL.</td><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Potassium (if hypokalemia is present) &#x00026; IV lidocaine can be added.</td></tr><tr><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">If PVC are seen but rare, replete w/bolus of magnesium or use an IV drip to consistently maintain magnesium level &#x02265;2.2 mg/dL.</td><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">If high-grade ectopy incl frequent PVCs, couplets, or <i>TdPs</i> are seen (&#x00026; cardiac function is normal), give isoproterenol (bolus if <i>TdPs</i>), or as continuous infusion if persistent high-grade ectopy or persistent <i>TdPs</i>.</td><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_2" rowspan="3" colspan="1" scope="row" style="text-align:left;vertical-align:middle;">If cardiac function is mild to moderately depressed, isoproterenol can be given but should be used w/caution for extended periods &#x00026; function followed closely.</td><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">An alternative to isoproterenol, esp in the setting of cardiac dysfunction, can be atrial pacing.&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_3" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Atrial pacing is preferred over ventricular pacing.</td></tr><tr><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_3" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">A transesophageal lead can be used in emergency or for short-term pacing until a temporary wire can be placed.</td></tr><tr><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">If systolic function is severely depressed, continue magnesium as first-line treatment.</td><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Death due to refractory arrhythmias has occurred despite treatment; thus ECMO should be considered for support through metabolic crises.</td></tr><tr><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">For <b>uncontrollable, hemodynamically unstable VT:</b></td><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DC cardioversion, pacing, &#x00026; consideration of ECMO support</td><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Backup support (e.g., ECMO) needs to be available as these drugs may potentiate or worsen arrhythmias.</td></tr><tr><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Electrolyte imbalance</b></td><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment as necessary to maintain normal levels of potassium, magnesium, &#x00026; glucose</td><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Electrolyte levels should be monitored during acute episodes of metabolic crisis.</td></tr><tr><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Hypothyroidism</b></td><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Levothyroxine treatment</td><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Thyroid function should be evaluated.</td></tr><tr><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Adrenal insufficiency</b></td><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cortisol replacement, typically hydrocortisone</td><td headers="hd_h_tango2-mea.T.acute_treatment_acute_metab_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">ECMO = extracorporeal membrane oxygenation; ICU = intensive care unit; IV = intravenous; PVC = premature ventricular contraction; <i>TdPs</i> = <i>torsade de pointes</i>; VF = ventricular fibrillation; VT = ventricular tachycardia</p></div></dd><dt>1. </dt><dd><div id="tango2-mea.TF.4.1"><p class="no_margin">Hemodialysis does not effectively remove circulating myoglobin and therefore is not indicated for the removal of excess serum myoglobin.</p></div></dd><dt>2. </dt><dd><div id="tango2-mea.TF.4.2"><p class="no_margin">Cardiac rhythmic disturbances that occur in individuals with <i>TANGO2</i>-related metabolic encephalopathy are predominantly ventricular tachyarrhythmias.</p></div></dd><dt>3. </dt><dd><div id="tango2-mea.TF.4.3"><p class="no_margin">The mechanisms for arrhythmia development are still being defined and thus acute treatment and long-term management remain unclear.</p></div></dd><dt>4. </dt><dd><div id="tango2-mea.TF.4.4"><p class="no_margin">Avoid medications that prolong the QT interval.</p></div></dd><dt>5. </dt><dd><div id="tango2-mea.TF.4.5"><p class="no_margin">Persistent ventricular arrhythmias despite these approaches are common.</p></div></dd><dt>6. </dt><dd><div id="tango2-mea.TF.4.6"><p class="no_margin">This can be done with a temporary pacing wire for longer-term pacing.</p></div></dd></dl></div></div></div><div id="tango2-mea.NonAcute_Presentation"><h4>Non-Acute Presentation</h4><div id="tango2-mea.T.routine_treatment_in_indivi" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Routine Treatment in Individuals with <i>TANGO2</i>-Related Metabolic Encephalopathy and Arrhythmias</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK476443/table/tango2-mea.T.routine_treatment_in_indivi/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tango2-mea.T.routine_treatment_in_indivi_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_tango2-mea.T.routine_treatment_in_indivi_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Manifestation/<br />Concern</th><th id="hd_h_tango2-mea.T.routine_treatment_in_indivi_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th><th id="hd_h_tango2-mea.T.routine_treatment_in_indivi_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consideration/Other</th></tr></thead><tbody><tr><td headers="hd_h_tango2-mea.T.routine_treatment_in_indivi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cardiac arrhythmias&#x000a0;<sup>1</sup></b></td><td headers="hd_h_tango2-mea.T.routine_treatment_in_indivi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Individuals w/documented ventricular arrhythmias typically undergo placement of an automated implantable cardioverter defibrillator.</td><td headers="hd_h_tango2-mea.T.routine_treatment_in_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Due to concerns for hypoglycemia, the appropriateness of long-term outpatient use of beta antiadrenergic blockade is unclear.</td></tr><tr><td headers="hd_h_tango2-mea.T.routine_treatment_in_indivi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hypothyroidism</b></td><td headers="hd_h_tango2-mea.T.routine_treatment_in_indivi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Levothyroxine</td><td headers="hd_h_tango2-mea.T.routine_treatment_in_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consider referral to an endocrinologist.</td></tr><tr><td headers="hd_h_tango2-mea.T.routine_treatment_in_indivi_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Seizures</b></td><td headers="hd_h_tango2-mea.T.routine_treatment_in_indivi_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatment w/antiepileptic medication</td><td headers="hd_h_tango2-mea.T.routine_treatment_in_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consider referral to a neurologist.</td></tr><tr><td headers="hd_h_tango2-mea.T.routine_treatment_in_indivi_1_1_1_3" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Ketogenic diet has been instituted in a few <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals w/refractory seizures. Acute metabolic crises after initiation of ketogenic diet have been reported.</td></tr><tr><td headers="hd_h_tango2-mea.T.routine_treatment_in_indivi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurodevelopmental delays</b></td><td headers="hd_h_tango2-mea.T.routine_treatment_in_indivi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Supportive therapies (e.g., PT, OT, speech therapy)</td><td headers="hd_h_tango2-mea.T.routine_treatment_in_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">OT = occupational therapy; PT = physical therapy</p></div></dd><dt>1. </dt><dd><div id="tango2-mea.TF.5.1"><p class="no_margin">Questions regarding definitive treatment remain.</p></div></dd></dl></div></div></div></div><div id="tango2-mea.Developmental_Delay__Intellec"><h4>Developmental Delay / Intellectual Disability Management Issues</h4><p>The following information represents typical management recommendations for individuals with developmental delay / intellectual disability in the United States; standard recommendations may vary from country to country.</p><p><b>Ages 0-3 years.</b> Referral to an early intervention program is recommended for access to occupational, physical, speech, and feeding therapy. In the US, early intervention is a federally funded program available in all states.</p><p><b>Ages 3-5 years.</b> In the US, developmental preschool through the local public school district is recommended. Before placement, an evaluation is made to determine needed services and therapies and an individualized education plan (IEP) is developed.</p><p><b>Ages 5-21 years</b></p><ul><li class="half_rhythm"><div>In the US, an IEP based on the individual's level of function should be developed by the local public school district. Affected children are permitted to remain in the public school district until age 21.</div></li><li class="half_rhythm"><div>Discussion about transition plans including financial, vocation/employment, and medical arrangements should begin at age 12 years. Developmental pediatricians can provide assistance with transition to adulthood.</div></li></ul><p><b>All ages.</b> Consultation with a developmental pediatrician is recommended to ensure the involvement of appropriate community, state, and educational agencies and to support parents in maximizing quality of life.</p><p>Consideration of private supportive therapies based on the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual's needs is recommended. Specific recommendations regarding type of therapy can be made by a developmental pediatrician.</p><p>In the US:</p><ul><li class="half_rhythm"><div>Developmental Disabilities Administration (DDA) enrollment is recommended. DDA is a public agency that provides services and support to qualified individuals. Eligibility differs by state but is typically determined by diagnosis and/or associated cognitive/adaptive disabilities.</div></li><li class="half_rhythm"><div>Families with limited income and resources may also qualify for supplemental security income (SSI) for their child with a disability.</div></li></ul></div><div id="tango2-mea.Motor_Dysfunction"><h4>Motor Dysfunction</h4><p><b>Gross motor dysfunction</b></p><ul><li class="half_rhythm"><div>Physical therapy is recommended to maximize mobility and to reduce the risk for later-onset orthopedic complications.</div></li><li class="half_rhythm"><div>Consider use of durable medical equipment as needed (e.g., wheelchairs, walkers, bath chairs, orthotics, adaptive strollers).</div></li><li class="half_rhythm"><div>For muscle tone abnormalities including hypertonia, consider involving appropriate specialists to aid in management of baclofen, Botox<sup>&#x000ae;</sup>, or orthopedic procedures.</div></li></ul><p><b>Fine motor dysfunction.</b> Occupational therapy is recommended for difficulty with fine motor skills that affect adaptive function such as feeding, grooming, dressing, and writing.</p><p><b>Oral motor dysfunction.</b> Assuming that the individual is safe to eat by mouth, feeding therapy &#x02013; typically from an occupational or speech therapist &#x02013; is recommended for <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals who have difficulty feeding.</p><p><b>Communication issues.</b> Consider evaluation for alternative means of communication (e.g., <a href="http://www.asha.org/NJC/AAC/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Augmentative and Alternative Communication</a> [AAC]) for individuals who have expressive language difficulties.</p></div></div><div id="tango2-mea.Prevention_of_Primary_Manifes"><h3>Prevention of Primary Manifestations</h3><p>Avoid triggers for acute metabolic crisis (e.g., prolonged fasting, dehydration, ketogenic diet).</p><p>Extreme vigilance for signs and symptoms of dehydration during intercurrent illnesses is indicated. Infusion of intravenous glucose during significant acute periods of systemic metabolic stress caused by infection or general anesthesia may be required to prevent significant catabolism.</p></div><div id="tango2-mea.Prevention_of_Secondary_Compl"><h3>Prevention of Secondary Complications</h3><p>Adequate hydration and alkalinization of the urine during an attack of rhabdomyolysis and myoglobinuria is recommended to prevent renal failure.</p><p>An "emergency" plan should be in place for both families and physicians to initiate appropriate steps to suppress acute catabolism and promote hydration in order to minimize the risk of life-threatening rhabdomyolysis and cardiac tachyarrhythmias in this disorder. Prior to determining the rate and amount of fluid administration, an echocardiogram to assess cardiac function should be obtained.</p></div><div id="tango2-mea.Surveillance"><h3>Surveillance</h3><p>Regular cardiology evaluation is appropriate for management of cardiac arrhythmias.</p><p>Annual monitoring of TSH and free T4 is recommended.</p><p>Follow up with a neurologist to manage epilepsy may be required.</p></div><div id="tango2-mea.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Avoid fasting, dehydration, and ketogenic diet.</p></div><div id="tango2-mea.Evaluation_of_Relatives_at_Ri"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to clarify the genetic status of apparently asymptomatic older and younger sibs of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of the <i>TANGO2</i> pathogenic variants in the family in order to identify as early as possible those who would benefit from prompt initiation of treatment and preventive measures.</p><p>See <a href="#tango2-mea.Related_Genetic_Counseling_Is">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="tango2-mea.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div><div id="tango2-mea.Other"><h3>Other</h3><p>Due to suspicion of mitochondrial dysfunction prior to diagnosis in several individuals, many have been treated with coenzyme Q<sub>10</sub>, riboflavin, and levocarnitine. The efficacy of these supplements in preventing metabolic crises remains unclear at present.</p></div></div><div id="tango2-mea.Genetic_Counseling"><h2 id="_tango2-mea_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="tango2-mea.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><i>TANGO2</i>-related metabolic encephalopathy and arrhythmias is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <i>TANGO2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Individuals with <i>TANGO2</i>-related metabolic encephalopathy and arrhythmias are not known to reproduce.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>TANGO2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="tango2-mea.Carrier_Heterozygote_Detectio"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>TANGO2</i> pathogenic variants in the family.</p></div><div id="tango2-mea.Related_Genetic_Counseling_Is"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#tango2-mea.Evaluation_of_Relatives_at_Ri">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="tango2-mea.Prenatal_Testing_and_Preimpla"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>TANGO2</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="tango2-mea.Resources"><h2 id="_tango2-mea_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>TANGO2 Research Foundation</b></div><div>300 Plaza Middlesex</div><div>Middletown 06457</div><div><b>Email:</b> info@tango2research.org</div><div><a href="https://tango2research.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.tango2research.org</a></div></li><li class="half_rhythm"><div><b>Metabolic Support UK</b></div><div>5 Hilliards Court, Sandpiper Way</div><div>Chester Business Park</div><div>Chester CH4 9QP </div><div>United Kingdom</div><div><b>Phone:</b> 0845 241 2173</div><div><b>Email:</b> contact@metabolicsupportuk.org</div><div><a href="https://www.metabolicsupportuk.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.metabolicsupportuk.org</a></div></li></ul></div><div id="tango2-mea.Molecular_Genetics"><h2 id="_tango2-mea_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="tango2-mea.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>TANGO2-Related Metabolic Encephalopathy and Arrhythmias: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK476443/table/tango2-mea.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tango2-mea.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_tango2-mea.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_tango2-mea.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_tango2-mea.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_tango2-mea.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_tango2-mea.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_tango2-mea.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/128989" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>TANGO2</i></a></td><td headers="hd_b_tango2-mea.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=128989" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">22q11<wbr style="display:inline-block"></wbr>​.21</a></td><td headers="hd_b_tango2-mea.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q6ICL3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Transport and Golgi organization protein 2 homolog</a></td><td headers="hd_b_tango2-mea.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=TANGO2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TANGO2</a></td><td headers="hd_b_tango2-mea.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=TANGO2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TANGO2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="tango2-mea.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="tango2-mea.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for TANGO2-Related Metabolic Encephalopathy and Arrhythmias (<a href="/omim/616830,616878" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK476443/table/tango2-mea.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tango2-mea.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/616830" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">616830</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">TRANSPORT AND GOLGI ORGANIZATION 2 HOMOLOG; TANGO2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/616878" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">616878</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">METABOLIC CRISES, RECURRENT, WITH RHABDOMYOLYSIS, CARDIAC ARRHYTHMIAS, AND NEURODEGENERATION; MECRCN</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>TANGO2</i> is approximately 50 kb in size and has multiple different <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> as a result of alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a>. Isoform a (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_152906.6" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_152906.6</a>) consists of one noncoding and eight coding exons. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK476443/#tango2-mea.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> The pathogenic variants reported to date include <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, and splice junction variants and small and large deletions [<a class="bk_pop" href="#tango2-mea.REF.kremer.2016.358">Kremer et al 2016</a>, <a class="bk_pop" href="#tango2-mea.REF.lalani.2016.347">Lalani et al 2016</a>] (see <a class="figpopup" href="/books/NBK476443/table/tango2-mea.T.tango2_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figtango2meaTtango2pathogenicvariants" rid-ob="figobtango2meaTtango2pathogenicvariants">Table 6</a>). Of the recurrent variants, the c.460G&#x0003e;A (p.Gly154Arg) <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is enriched in the Hispanic-Latino population and the <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 3-9 <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> has been identified in individuals of European origin.</p><div id="tango2-mea.T.tango2_pathogenic_variants" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p><i>TANGO2</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK476443/table/tango2-mea.T.tango2_pathogenic_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tango2-mea.T.tango2_pathogenic_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_tango2-mea.T.tango2_pathogenic_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_tango2-mea.T.tango2_pathogenic_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_tango2-mea.T.tango2_pathogenic_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_tango2-mea.T.tango2_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.4delT</td><td headers="hd_h_tango2-mea.T.tango2_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Cys2AlafsTer35</td><td headers="hd_h_tango2-mea.T.tango2_pathogenic_variants_1_1_1_3" rowspan="6" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_152906.6" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_152906<wbr style="display:inline-block"></wbr>​.6</a><br /><a href="https://www.ncbi.nlm.nih.gov/protein/NP_690870.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_690870<wbr style="display:inline-block"></wbr>​.3</a></td></tr><tr><td headers="hd_h_tango2-mea.T.tango2_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.418C&#x0003e;T</td><td headers="hd_h_tango2-mea.T.tango2_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg140Ter</td></tr><tr><td headers="hd_h_tango2-mea.T.tango2_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.460G&#x0003e;A</td><td headers="hd_h_tango2-mea.T.tango2_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly154Arg</td></tr><tr><td headers="hd_h_tango2-mea.T.tango2_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.605+1G&#x0003e;A</td><td headers="hd_h_tango2-mea.T.tango2_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_tango2-mea.T.tango2_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Exons 3&#x02013;9 (34 kb) del</td><td headers="hd_h_tango2-mea.T.tango2_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_tango2-mea.T.tango2_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Exons 4&#x02013;6 (9 kb) del</td><td headers="hd_h_tango2-mea.T.tango2_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> TANGO2 belongs to the transport and Golgi organization family, whose members are predicted to play roles in secretory protein loading in the endoplasmic reticulum. Depletion of this gene in <i>Drosophila</i> S2 cells causes fusion of the Golgi with the ER. In mouse tissue culture cells, this protein co-localizes with a mitochondrial-targeted mCherry protein and displays very low levels of co-localization with Golgi and peroxisomes (provided by RefSeq; 4/2016).</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>TANGO2</i>-related metabolic encephalopathy and arrhythmias is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. Biallelic pathogenic variants resulting in complete or partial loss of protein function is likely the underlying basis of this disorder.</p></div><div id="tango2-mea.References"><h2 id="_tango2-mea_References_">References</h2><div id="tango2-mea.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="tango2-mea.REF.dines.2019.601">Dines JN, Golden-Grant K, LaCroix A, Muir AM, Cintr&#x000f3;n DL, McWalter K, Cho MT, Sun A, Merritt JL, Thies J, Niyazov D, Burton B, Kim K, Fleming L, Westman R, Karachunski P, Dalton J, Basinger A, Ficicioglu C, Helbig I, Pendziwiat M, Muhle H, Helbig KL, Caliebe A, Santer R, Becker K, Suchy S, Douglas G, Millan F, Begtrup A, Monaghan KG, Mefford HC. TANGO2: expanding the clinical phenotype and spectrum of pathogenic variants. <span><span class="ref-journal">Genet Med. </span>2019;<span class="ref-vol">21</span>:601–7.</span> [<a href="/pmc/articles/PMC6752277/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6752277</span></a>] [<a href="/pubmed/30245509" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30245509</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tango2-mea.REF.elsayed.2010.7">Elsayed EF, Reilly RF. Rhabdomyolysis: a review, with emphasis on the pediatric population. <span><span class="ref-journal">Pediatr Nephrol. </span>2010;<span class="ref-vol">25</span>:7–18.</span> [<a href="/pubmed/19529963" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19529963</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tango2-mea.REF.kremer.2016.358">Kremer LS, Distelmaier F, Alhaddad B, Hempel M, Iuso A, Kupper C, Muhlhausen C, Kovacs-Nagy R, Satanovskij R, Graf E, Berutti R, Eckstein G, Durbin R, Sauer S, Hoffmann GF, Strom TM, Santer R, Meitinger T, Klopstock T, Prokisch H, Haack TB. Bi-allelic truncating mutations in tango2 cause infancy-onset recurrent metabolic crises with encephalocardiomyopathy. <span><span class="ref-journal">Am J Hum Genet. </span>2016;<span class="ref-vol">98</span>:358–62.</span> [<a href="/pmc/articles/PMC4746337/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4746337</span></a>] [<a href="/pubmed/26805782" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26805782</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tango2-mea.REF.lalani.2016.347">Lalani SR, Liu P, Rosenfeld JA, Watkin LB, Chiang T, Leduc MS, Zhu W, Ding Y, Pan S, Vetrini F, Miyake CY, Shinawi M, Gambin T, Eldomery MK, Akdemir ZH, Emrick L, Wilnai Y, Schelley S, Koenig MK, Memon N, Farach LS, Coe BP, Azamian M, Hernandez P, Zapata G, Jhangiani SN, Muzny DM, Lotze T, Clark G, Wilfong A, Northrup H, Adesina A, Bacino CA, Scaglia F, Bonnen PE, Crosson J, Duis J, Maegawa GH, Coman D, Inwood A, McGill J, Boerwinkle E, Graham B, Beaudet A, Eng CM, Hanchard NA, Xia F, Orange JS, Gibbs RA, Lupski JR, Yang Y. Recurrent muscle weakness with rhabdomyolysis, metabolic crises, and cardiac arrhythmia due to bi-allelic tango2 mutations. <span><span class="ref-journal">Am J Hum Genet. </span>2016;<span class="ref-vol">98</span>:347–57.</span> [<a href="/pmc/articles/PMC4746334/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4746334</span></a>] [<a href="/pubmed/26805781" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26805781</span></a>]</div></li></ul></div></div><div id="tango2-mea.Chapter_Notes"><h2 id="_tango2-mea_Chapter_Notes_">Chapter Notes</h2><div id="tango2-mea.Author_Notes"><h3>Author Notes</h3><p><b>Author websites</b></p><ul><li class="half_rhythm"><div><a href="https://www.bcm.edu/people/view/eema-lalani-m-d/b253d6f0-ffed-11e2-be68-080027880ca6" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Seema R Lalani, MD</a></div></li><li class="half_rhythm"><div><a href="https://medicine.iu.edu/departments/genetics/faculty/38482/graham-brett/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Brett H Graham, MD, PhD</a></div></li><li class="half_rhythm"><div><a href="https://www.bcm.edu/people/view/lindsay-burrage-m-d-ph-d/baylor-college-of-medicine-meet-our-team-physicians-a-l-genetics-clinics/b164351a-ffed-11e2-be68-080027880ca6/54d102e0-bdfc-4315-806f-3bf60a1612dc" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Lindsay Burrage, MD, PhD</a></div></li><li class="half_rhythm"><div><a href="https://www.bcm.edu/people/view/yi-chen-lai-m-d/b2849881-ffed-11e2-be68-080027880ca6" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Yi-Chen Lai, MD</a></div></li><li class="half_rhythm"><div><a href="https://www.bcm.edu/people/view/fernando-scaglia-m-d/b17bf6de-ffed-11e2-be68-080027880ca6" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fernando Scaglia, MD</a></div></li><li class="half_rhythm"><div><a href="https://www.bcm.edu/people/view/claudia-soler-alfonso-m-d-f-a-c-m-g/488e837e-4a93-11e3-9de7-005056b104be" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Claudia Soler-Alfonso, MD</a></div></li><li class="half_rhythm"><div><a href="https://www.bcm.edu/people/view/christina-miyake-m-d-m-s/b16d5031-ffed-11e2-be68-080027880ca6" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Christina Y Miyake, MD</a></div></li></ul></div><div id="tango2-mea.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>20 December 2018 (ma) Comprehensive update posted live</div></li><li class="half_rhythm"><div>25 January 2018 (sw) Review posted live</div></li><li class="half_rhythm"><div>23 September 2017 (srl) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK476443</span><span class="label">PMID: <a href="/pubmed/29369572" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">29369572</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/cdsp/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/tardbp-als/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK476443&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK476443/?report=reader">PubReader</a></li><li><a href="/books/NBK476443/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK476443" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK476443" style="display:none" title="Cite this Page"><div class="bk_tt">Lalani SR, Graham B, Burrage L, et al. TANGO2-Related Metabolic Encephalopathy and Arrhythmias. 2018 Jan 25 [Updated 2018 Dec 20]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK476443/pdf/Bookshelf_NBK476443.pdf">PDF version of this page</a> (450K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#tango2-mea.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#tango2-mea.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#tango2-mea.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#tango2-mea.Genetically_Related_Allelic_D" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#tango2-mea.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#tango2-mea.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#tango2-mea.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#tango2-mea.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#tango2-mea.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#tango2-mea.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#tango2-mea.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=128989[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">TANGO2</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=4495180" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4495180" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4495180" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=4495180" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/22593918" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Propionic Acidemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Propionic Acidemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Shchelochkov OA, Carrillo N, Venditti C. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31804789" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fructose-1,6-Bisphosphatase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fructose-1,6-Bisphosphatase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bijarnia-Mahay S, Bhatia S, Arora V. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301466" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Catecholaminergic Polymorphic Ventricular Tachycardia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Catecholaminergic Polymorphic Ventricular Tachycardia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Napolitano C, Priori SG, Bloise R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301763" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Very Long-Chain Acyl-Coenzyme A Dehydrogenase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Very Long-Chain Acyl-Coenzyme A Dehydrogenase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Leslie ND, Valencia CA, Strauss AW, Zhang K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301503" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Disorders of Intracellular Cobalamin Metabolism</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Disorders of Intracellular Cobalamin Metabolism<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sloan JL, Carrillo N, Adams D, Venditti CP. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=29369572" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=29369572" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e041836dde0891169349a51">TANGO2-Related Metabolic Encephalopathy and Arrhythmias - GeneReviews®</a><div class="ralinkpop offscreen_noflow">TANGO2-Related Metabolic Encephalopathy and Arrhythmias - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:17:26-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal104&amp;ncbi_phid=CE8BCC20E04074010000000007140289&amp;ncbi_session=CE8BCC20E0418351_1812SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK476443%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK476443&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK476443/&amp;ncbi_pagename=TANGO2-Related Metabolic Encephalopathy and Arrhythmias - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8BCC20E0418351_1812SID /projects/books/PBooks@5.22 portal104 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>